Form 4: Cytek Biosciences CLO Reports Routine Equity Transactions

Cytek Biosciences' Chief Legal Officer, Valerie Barnett, reported routine equity transactions including RSU vesting, stock option grants, and shares withheld for tax obligations.

Summary

• Valerie Barnett, Chief Legal Officer of Cytek Biosciences, Inc. (CTKB), reported multiple equity transactions on March 10, 2026.
• Transactions included the acquisition of common stock through the vesting of Restricted Stock Units (RSUs) totaling 4,908, 10,313, and 14,501 shares.
• Concurrently, shares were disposed of to satisfy tax withholding obligations related to RSU vesting: 1,761 shares, 4,247 shares, and 5,740 shares, all at a price of $4.23 per share.
• Barnett also acquired 120,114 employee stock options with an exercise price of $4.23, which will vest over 4 years starting April 10, 2026.
• Additionally, 226,453 Restricted Stock Units were acquired, which will vest over 4 years with specific quarterly schedules starting May 18, 2026.
• Following these transactions, Valerie Barnett's direct beneficial ownership of common stock was 134,436 shares, along with 120,114 employee stock options and 226,453, 14,734, 61,884, and 130,512 Restricted Stock Units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports routine equity compensation events for an executive, which are expected and do not indicate any significant positive or negative operational or financial developments for the company.

Positives

• The grant of 120,114 employee stock options and 226,453 Restricted Stock Units indicates continued long-term incentive alignment between management and shareholders.
• The vesting of RSUs and stock options represents the realization of previously granted equity compensation, reflecting the company's performance over time.

Negatives

• The disposal of 11,748 shares (1,761 + 4,247 + 5,740) for tax withholding purposes, while routine, reduces the direct common stock holdings of the Chief Legal Officer.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, beyond the vesting schedules for equity awards.

Management Comments

• No notable quotes or paraphrased statements from company management are provided in this Form 4 filing, other than the signature of Valerie Barnett.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as those reported in this Form 4, are common across the biotechnology and life sciences industry. Equity compensation, including RSUs and stock options, is a standard practice for attracting and retaining key executives in competitive sectors like Cytek Biosciences' flow cytometry and cell analysis market. These transactions do not typically signal a shift in broader industry trends but rather reflect standard compensation practices.

Comparison to Industry Standards

• StockSavvy.ai observes that the equity compensation structure, involving both Restricted Stock Units and employee stock options with multi-year vesting schedules, aligns with common practices for executive compensation in the U.S. technology and life sciences sectors.
• Companies like Thermo Fisher Scientific, Danaher Corporation, and Bio-Rad Laboratories often utilize similar long-term incentive plans to align executive interests with shareholder value creation.
• The vesting periods of 4 years are standard for promoting long-term retention and performance.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine compensation events. The vesting and subsequent tax sales are part of the expected dilution from equity compensation plans.
• Employees: Reflects standard executive compensation practices, which can be a positive for employee morale and retention if seen as fair and competitive.

Next Steps

• Continued vesting of employee stock options monthly, starting April 10, 2026, over 4 years.
• Continued vesting of 226,453 RSU Award shares on May 18, August 18, November 18, and March 10 annually over 4 years, starting May 18, 2026.
• Continued vesting of 14,734 RSU Award shares on May 18, August 18, November 18, and March 10 annually over 4 years, starting May 18, 2023.
• Continued vesting of 61,884 RSU Award shares on May 18, August 18, November 18, and March 10 annually over 4 years, starting May 18, 2024.
• Continued vesting of 130,512 RSU Award shares on May 18, August 18, November 18, and March 10 annually over 4 years, starting May 18, 2025.

Key Dates

Keywords

Cytek Biosciences, CTKB, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Stock Options, Valerie Barnett, Chief Legal Officer, Vesting, Tax Withholding